Europe
Over the course of 2018, the FDA approved 59 different novel drugs that range for the treatment of various cancers, chronic obstructive pulmonary disease (COPD), traveler’s diarrhea, migraine headaches and more.
Yesterday, shareholders filed for a class action lawsuit against Tesaro in Delaware federal court, alleging that the merger is based on misleading financial analyses filed with the U.S. Securities and Exchange Commission (SEC).
In an interview with CNBC Monday, Novartis Chief Executive Officer Vas Narasimhan noted that the company is looking to become an entity that doesn’t draw its profits from treating disease, but will make money by providing cures.
Last year’s sole mega-deal, the acquisition of Dublin-based Shire by Japan-based Takeda Pharmaceutical is finally closed. Takeda, 237 years old, is now a top 10 international drug company.
Adaptimmune Therapeutics plc today announced that the Safety Review Committee (SRC) has endorsed dose escalation in the ongoing ADP-A2AFP (AFP) study in patients with hepatocellular carcinoma (liver cancer) to the second dose cohort.
Agreement targets the development of low volume and high sensitivity multiplex assays for aqueous humor protein profiling for biomarker identification and validation in support of drug discovery in ophthalmology
$ 26 M FINANCING ROUND (SERIES B) INCLUDES CELGENE, GT HEALTHCARE CAPITAL PARTNERS AND EVOTEC
Key preparatory steps to conduct phase IIb trials initiated, including CMC and regulatory activities in the EU and US
Karolinska Development’s portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD).
IDE application submitted to the FDA for HEMOSNOWTM
PRESS RELEASES